Graft Versus Host Disease: Opportunity Analysis and Forecasts to 2028

1.1 List of Tables
1.2 List of Figures

2.1 Strong Growth Expected in the GvHD Marketplace from 2018–2028
2.2 Lack of Consensus on Clinical Trial Endpoints
2.3 GvHD Unmet Needs Expected to Be Partially Addressed
2.4 Opportunity Remains for GvHD Prophylaxis Candidates
2.5 Jakafi Approval for Both Acute and Chronic GvHD Will Drive Sales
2.6 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification and Prognosis
4.2.1 Acute GvHD
4.2.2 Chronic GvHD

Table 1: GvHD: Key Metrics in the 7MM
Table 2: Grading System of Organ Involvement in a GvHD
Table 3: Global Severity of Chronic GvHD
Table 4: Risk Factors for GvHD
Table 5: Treatment Guidelines for GvHD
Table 6: Innovative Approaches for GvHD, 2019
Table 7: Clinical Benchmark of Key Pipeline Drugs – GvHD Treatment
Table 8: Clinical Benchmark of Key Pipeline Drugs – GvHD Prophylaxis
Table 9: Commercial Benchmark of Key Pipeline Drugs – GvHD Treatment
Table 10: Commercial Benchmark of Key Pipeline Drugs – GvHD Prophylaxis
Table 11: Key Events Impacting Sales for GvHD, 2018–2028
Table 12: GvHD Market – Global Drivers and Barriers, 7MM, 2018–2028
Table 13: Key Historical and Projected Approval/Launch Dates for GvHD
Table 14: Key Historical and Projected Patent Expiry Dates for GvHD
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for GvHD in 2018 and 2028
Figure 2: Competitive Assessment of the Pipeline GvHD Treatments Benchmarked Against the SOC, Methotrexate
Figure 3: Pathology of Acute GvHD
Figure 4: 7MM, Diagnosed Incidence of aGvHD per 100 Diagnosed Incident First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 5: 7MM, Diagnosed Incidence of cGvHD per 100 Diagnosed Incident First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 6: Sources Used for First Allogeneic HSCT
Figure 7: Sources Used for aGvHD and cGvHD in First Allogeneic HSCT
Figure 8: Sources Used for aGvHD Grades
Figure 9: Sources Used for cGvHD Severity
Figure 10: Sources Used for 100-Day Mortality of aGvHD and One-Year Mortality of cGvHD
Figure 11: Sources Used for Three-Year Diagnosed Prevalent Cases of aGvHD and cGvHD
Figure 12: 7MM, Diagnosed Incident Cases of First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
Figure 13: 7MM, Diagnosed Incident Cases of aGvHD in First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
Figure 14: 7MM, Diagnosed Incident Cases of cGvHD in First Allogeneic HSCT Cases, Men and Women, All Ages, 2018
Figure 15: 7MM, Age-Specific Diagnosed Incident Cases of aGvHD and cGvHD in First Allogeneic HSCT Cases, Men and Women, 2018
Figure 16: 7MM, Diagnosed Incident Cases of aGvHD by Grade, Men and Women, All Ages, 2018
Figure 17: 7MM, Diagnosed Incident Cases of cGvHD by Severity, Men and Women, All Ages, 2018
Figure 18: 7MM, 100-Day Mortality in Diagnosed Incident Cases of aGvHD, Men and Women, All Ages, 2018 and 2028
Figure 19: 7MM, One-Year Mortality in Diagnosed Incident Cases of cGvHD, Men and Women, All Ages, 2018
Figure 20: 7MM, Three-Year Diagnosed Prevalent Cases of aGvHD, Men and Women, All Ages, 2018
Figure 21: 7MM, Three-Year Diagnosed Prevalent Cases of cGvHD, Men and Women, All Ages, 2018
Figure 22: Unmet Needs and Opportunities in GvHD
Figure 23: Overview of the Development Pipeline in GvHD
Figure 24: Key Phase II/III Trials for Pipeline Agents Expected to Be Licensed for GvHD in the 7MM During the Forecast Period
Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs for GvHD Treatment Benchmarked Against the SOC, methotrexate
Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs for GvHD Prophylaxis Benchmarked Against the SOC, methylprednisolone
Figure 27: 7MM Sales Forecast by Country for GvHD in 2018 and 2028
Figure 28: 7MM Sales Forecast by Class for GvHD in 2018 and 2028
Figure 29: 7MM Sales Forecast by Patient Population for GvHD in 2018 and 2028
Figure 30: Sales Forecast by Class for GvHD in the US in 2018 and 2028
Figure 31: Sales Forecast by Class for GvHD in the 5EU in 2018 and 2028
Figure 32: Sales Forecast by Class for GvHD in Japan in 2018 and 2028